Newborn Metabolic Screening Market is Predicted to Reach US$ 857.4 Billion by 2034, Expanding at a CAGR of 9.2% | Fact.MR

The size of the newborn metabolic screening market is expected to reach US$ 355.1 million in 2024. A high compound annual growth rate (CAGR) of 9.2% is expected to drive the market through 2034. This upward trend is estimated to drive the market to a high value of US$ 857.4 million by 2034.

As knowledge of metabolic disorders that impact infants has increased, so too has the use of newborn metabolic screening tests. This is because it can truthfully gauge an infant's health and detect a variety of conditions or congenital abnormalities so that the proper medical attention and potentially even the infant's survival can be provided. Due to this, during the forecast period, there is expected to be an increase in demand for neonatal metabolic screening.

For More Insights into the Market, Request a Sample of this Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=9618

Which are the Factors that Challenge the Development of the Newborn Metabolic Screening Market?

"Lack of Healthcare Modernization and Skilled Professionals Affect the Market Negatively

The major barriers hindering the newborn screening market growth are the health sector's failure to modernize infrastructure and a shortage of individuals possessing the needed education and experience. For instance, because newborn screening is not yet widely utilized in the Asia Pacific, additional research and mentoring are needed.

Developing nations with large populations and a lack of skilled personnel are available. Upgraded medical systems in developing nations are affected by high population densities, lower and middle income levels, and poor medical treatment.

Country-wise Insights

The North America newborn metabolic screening market is gearing up for promising growth, prophesying a steady CAGR of 9.4% through 2034. This is because of the high rate of birth abnormalities in the region, strict local government regulations, an excellent healthcare system, and recent innovations in newborn metabolic screening technologies made by regional players.

In this region, the United States will lead in the newborn metabolic screening market, enjoying a large regional market share of 78.7% in 2024.

East Asian newborn metabolic screening market is going for average growth, targeting 9.6% CAGR through 2034. Expansion of newborn screening participation programs by various government health care regulatory agencies and implementing the same for a wider population base primarily drives the growth here.

In 2024, China would likely dominate the spotlight as one of the major players in the newborn metabolic screening market, with an estimated regional share of 67.2%.

Category-wise Insights

During 2024, the type of test of sickle cell disease segment is expected to be leading and holds a prominent 32.5% market share. However, the hospital segment will dominate the newborn metabolic screening market and has a prominent 40.3% market share during 2024.

Sickle cell disease segment is assumed to command a 30.3% share in the newborn metabolic screening market by 2034. The usage of the sickle cell disease test type is expected to surge at a CAGR of 8.4% during 2034. Sickle cell disease occurs more frequently in newborns. Sickle cell disease is present in approximately 2,000 newborns every year in the United States. Screening is therefore essential for early detection.

Competitive Landscape

Major companies operating in the newborn metabolic screening market are PerkinElmer, Bio-Rad Laboratories, Trivitron Healthcare Private Limited, BioMedomics, Inc., Luminex Corporation, MP BIOMEDICALS, Synergy Medical Systems LLP, Agilent Technologies, Inc., Thermo Fisher Scientific, Inc., Zivak Technologies, Covidien Plc, AB Sciex LLC, Waters Corp., Masimo Corp., and Natus Medical Inc.

Firms are aligning themselves intentionally to take advantage of the competitive advantage, expecting the profitable business offered by the new metabolic screening market projection. Others focus on new advanced technology, using intricate screening methods to enhance accuracy and broaden the range of diseases that can be diagnosed.

There are those who prioritize pricing more to gain access to a larger market for screenings. In order to be at the leading edge of medical breakthroughs, most players form deliberate relationships with research centers and healthcare practitioners. Companies attempt to adapt rapidly to new trends through continuous investment in research and development. Overall, the competitive landscape is characterized by a focus on technological superiority, user-friendliness, as well as partnerships.

Recent Advances

September 2023, Mylab Discovery Solutions launched the patent-pending point-of-care device, MyNeoShield for Newborns, a revolutionary step in newborn screening. The device is set to revolutionize the face of newborn care by reducing the cost, enhancing accessibility, and accelerating screening.

In June 2022, in a partnership with the American Society of Hematology (ASH), Novartis AG started providing six additional countries in Africa with the same technology currently being used in Ghana to track and share sickle cell disease diagnosis data for newborns. Through this partnership, the current newborn screening consortium is set to expand into new areas.

During September 2020, leading organizations committed to rare medical disorders, including Orchard Therapeutics, Sarepta Therapeutics, Inc., BioMarin Pharmaceutical Inc., Retrophin, Inc., and the EveryLife Foundation for Rare Diseases, came together to evaluate how accurately newborn screening in the United States can identify all infants who were helped by new therapies in the proper manner.

Browse Full Report:https://www.factmr.com/report/newborn-metabolic-screening-market

Segmentation of Newborn Metabolic Screening Market Analysis

By Test Type:

Galactosemia
Sickle Cell Disease
Cystic Fibrosis
Toxoplasmosis
Methylmalonic Acidemia
Maple Syrup Urine Disease
Tyrosinemia
Citrullinema, Medium Chain Acyl CoA Dehydrogenase Deficiency
By Sample:

Coronary Artery Diseases
Chronic Heart Failure
By End User:

Hospitals
Ambulatory Surgical Centers
Independent Catherization Labs
By Region:

North America
Latin America
East Asia
South Asia and Pacific
Western Europe
Eastern Europe
The Middle East and Africa

Check out More Related Studies Published by Fact.MR:

Canine Separation Anxiety Treatment Market
https://www.factmr.com/report/1490/canine-separation-anxiety-treatment-market
Omics Based Clinical Trials Market
https://www.factmr.com/report/omics-based-clinical-trials-market
Glioblastoma Multiforme Treatment Market
https://www.factmr.com/report/glioblastoma-multiforme-treatment-market
Medical Foam Market
https://www.factmr.com/report/medical-foam-market

Contact:

US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232
Email: sales@factmr.com

About Fact.MR

We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.